<DOC>
	<DOCNO>NCT02952508</DOCNO>
	<brief_summary>This study evaluate CLR 131 patient select B-cell malignancy ( multiple myeloma ( MM ) , indolent chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) , lymphoplasmacytic lymphoma ( LPL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) , diffuse large B-cell lymphoma ( DLBCL ) previously treat standard therapy underlying malignancy .</brief_summary>
	<brief_title>Study CLR 131 Relapsed Refractory Select B-Cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>All Patients Histologically cytologically confirm MM ; CLL/SLL , LPL , MZL ; MCL OR histologically proven , de novo , DLBCL ECOG performance status 0 2 18 year age old Life expectancy least 6 month Platelets ≥ 100,000/µL ( fulldose anticoagulation therapy use , platelet ≥ 150,000/µL require ) WBC count ≥ 3000/µL Absolute neutrophil count ≥ 1500/µL Hemoglobin ≥ 9 g/dL ( last transfusion , , must least 1 week prior study registration , transfusion allow registration dose ) Estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2 Alanine aminotransferase &lt; 3 × upper limit normal ( ULN ) Bilirubin &lt; 1.5 × ULN International normalize ratio ( INR ) &lt; 2.5 If patient fulldose anticoagulation therapy , anticoagulation therapy must reversible reversal anticoagulation therapy must lifethreatening , judge Investigator Patients undergone stem cell transplant must least 100 day transplant Patient judge Investigator initiative mean compliant protocol within geographical proximity make require study visit Patient legal representative ability read , understand , provide write informed consent initiation studyrelated procedure Female patient childbearing potential must negative pregnancy test within 24 hour enrollment Women childbearing potential men able father child must agree use effective method contraception ( eg , oral contraceptive , doublebarrier method condom diaphragm , intrauterine device , Norplant , DepoProvera ) study 12 month follow administration study drug Patients Multiple Myeloma At least 2 prior regimen 5 , must include least 1 approve proteasome inhibitor ( bortezomib carfilzomib ) least 1 approve immunomodulatory agent ( thalidomide , lenalidomide , pomalidomide ) , without maintenance therapy , unless patient ineligible receive agent . Bone marrow biopsy within 28 day CLR 131 infusion demonstrate least 5 % plasma cell involvement Progressive disease define follow : 25 % increase serum Mprotein low response value ( ) last therapy and/or absolute increase serum Mprotein ≥ 0.5 g/dL 25 % increase urine Mprotein low response value ( ) last therapy and/or absolute increase urine Mprotein ≥ 200 mg/24 h 25 % increase bone marrow plasma cell percentage low response value ( ) last therapy . Absolute bone marrow plasma cell percentage must ≥ 10 % unless prior CR absolute bone marrow plasma cell percentage must ≥ 5 % . New onset hypercalcemia &gt; 11.5 mg/dL Measurable disease define follow : Serum Mprotein &gt; 0.5 g/dL Urine Mprotein &gt; 200 mg/24 h Serum FLC assay : Involved FLC level ≥ 10 mg/dL provide serum FLC ratio abnormal . Measurable plasmacytoma Patients nonsecretors consider accrual casebycase basis Sponsor require Investigator plan define PD prior enrollment assess clinical benefit treatment . Patients Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , Lymphoplasmacytic Lymphoma , Marginal Zone Lymphoma Prior treatment least 2 4 prior regimen , may include chemotherapy , approve antiCD20 antibody without maintenance therapy , approve targeted agent , unless patient ineligible receive agent Patients Helicobacter pylori+ mucosaassociated lymphoid tissue lymphoma must receive 1 prior antibiotic regimen H pylorus At least 1 measurable nodal lesion long diameter &gt; 15 mm 1 measurable extranodal lesion ( eg , hepatic nodule ) long diameter &gt; 10 mm Patients Mantle Cell Lymphoma Prior treatment least 1 2 prior regimen At least 1 measurable nodal lesion long diameter &gt; 15 mm 1 measurable extranodal lesion ( eg , hepatic nodule ) long diameter &gt; 10 mm Patients Diffuse Large BCell Lymphoma Relapsed refractory combination chemotherapy DLBCL contain rituximab anthracycline . Relapsed disease define either recurrence disease CR PD achieve partial response ( PR ) SD . Refractory disease define failure achieve least SD 1 line therapy PD ≤ 3 month recent chemotherapy regimen . One additional therapy stem cell transplant DLBCL allow . At least 1 measurable nodal lesion long diameter &gt; 15 mm 1 measurable extranodal lesion ( eg , hepatic nodule ) long diameter &gt; 10 mm Ongoing Grade 2 great toxicity due previous therapy . Stable , tolerable Grade 2 AEs ( eg , neuropathy ) may allow . Prior externalbeam RT result great 20 % total bone marrow receive great 20 Gy . Prior total body hemibody irradiation Extradural tumor contact spinal cord tumor locate swell response therapy may impinge upon spinal cord Central nervous system involvement unless previously treat surgery radiotherapy patient neurologically stable corticosteroid For patient CLL/SLL , LPL , MZL , transformation aggressive form NHL Ongoing chronic immunosuppressive therapy Clinically significant bleeding event within prior 6 month Ongoing antiplatelet therapy ( except lowdose aspirin [ eg , 81 mg daily ] cardioprotection ) PTT &gt; 1.3 × ULN INR &gt; 2.5 Radiation therapy , chemotherapy , immunotherapy , investigational therapy within 2 week eligibilitydefining bone marrow biopsy . History hypersensitivity iodine Any concomitant serious illness organ system dysfunction opinion Investigator would either compromise patient safety interfere evaluation safety test drug include , limited , myelodysplastic syndrome ; New York Heart Association class IIIIV heart disease ; unstable angina pectoris ; serious cardiac arrhythmia require medication pacemaker/automatic implantable cardioverter defibrillator ; myocardial infarction within past 6 month ; uncontrolled hypertension ; severe peripheral vascular disease ; ongoing hemodialysis peritoneal dialysis ; poorly control severe chronic obstructive pulmonary disease ; ongoing/active infection require antibiotic ; uncontrolled hypothyroidism hyperthyroidism Major surgery within 6 week enrollment Known history human immunodeficiency virus , hepatitis C , hepatitis B infection Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>